98%
921
2 minutes
20
The knee abduction moment (KAM) is often chosen as target of intervention studies to reduce anterior cruciate ligament injury risk. Outcome variables such as the KAM should be reproducible and responsive to change. This study critically evaluated the suitability of the KAM as an outcome variable for sidestepping interventions. Firstly, peak KAM effect sizes from either a within-day technique manipulation or long-term intervention studies were extracted using a systematic literature search. Effect sizes varied substantially from small to large effects. Secondly, power reporting practice across intervention studies was evaluated and was found to be generally not reproducible. Thirdly, KAM profiles were digitised to establish the consistency of reported KAM signals and to establish a representative KAM profile. Lastly, median KAM effect sizes from a within-day technique manipulation and long-term interventions were separately combined with the representative KAM profile for a hypothetical KAM reduction input to a waveform-level sample size estimation analysis. Sample sizes to observe a reduction of the median KAM effect size were ∼255 for a within-day technique manipulation and ∼360 long-term interventions. Intervention studies tended to observe smaller effect sizes than were calculated in their power analysis. Sample sizes needed to power hypothetical KAM reduction studies with median effect sizes were somewhat prohibitive. These results support the accumulating evidence that the KAM is not a suitable primary outcome measure against which intervention studies should be designed and evaluated.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jbiomech.2025.112896 | DOI Listing |
CNS Neurosci Ther
September 2025
College of Biomedical Engineering and Technology, Tianjin Medical University, Tianjin, China.
Background: Neurological diseases such as stroke or Parkinson's disease are often accompanied by weakening or loss of proprioception, which seriously affects the motor control ability of the patients. However, proprioception rehabilitation is challenging due to the pain caused by impaired joints and the hard efforts that patients have to make during training. This study investigated the cross-transfer effect of short-term visuomotor training to the untrained wrist from the trained wrist, from both views of behavioral results and brain activity analyses.
View Article and Find Full Text PDFJ Med Internet Res
September 2025
Department of Precision Medicine, Faculty of Health, Medicine and Life Sciences, Maastricht University, Universiteitssingel 40, Maastricht, 6229 ER, The Netherlands, 31 433883549.
Background: Making informed decisions about clinical trial participation can be overwhelming for patients due to the complexity of trial information, potential risks and benefits, and the emotional burden of a recent diagnosis. Patient decision aids (PDAs) simplify this process by providing clear information on treatment options, empowering patients to actively participate in shared decision-making with their doctors. While PDAs have shown promise in various health care contexts, their use in clinical trials, particularly in the form of trial-specific patient decision aids (tPDAs), remains underused.
View Article and Find Full Text PDFNeuropsychopharmacol Rep
September 2025
Trivedi Science Research Laboratory Pvt. Ltd., Thane (W), Maharashtra, India.
Reduced physical activities, social support, old age, and increased exposure to regular stressful life events are crucial factors for poor mental health. Although several medicines are available to support mental health-related symptoms, due to more side effects and non-compliance for long-term use, these conventional medicines are not appropriate to tackle these symptoms. In this context, the study aimed to determine whether spiritual energy therapy with an experienced spiritual energy practitioner could manage adults' psychological and mental health-related symptoms.
View Article and Find Full Text PDFJ Dermatolog Treat
December 2025
Department of Dermatology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Background: Ivarmacitinib (SHR0302), a selective Janus kinase-1 inhibitor, is a novel treatment for moderate-to-severe atopic dermatitis (AD).
Objectives: This post hoc analysis evaluated the impact of early itch relief with ivarmacitinib on quality of life (QoL), working productivity, and sleep quality in affected patients.
Methods: Data from ivarmacitinib treatment groups in a phase III trial (NCT04875169) were analyzed.
Biom J
October 2025
Novella Clinical Full Service, IQVIA, Melbourne, Australia.
Phase I dose escalation trials in oncology generally aim to find the maximum tolerated dose. However, with the advent of molecular-targeted therapies and antibody drug conjugates, dose-limiting toxicities are less frequently observed, giving rise to the concept of optimal biological dose (OBD), which considers both efficacy and toxicity. The estimand framework presented in the addendum of the ICH E9(R1) guidelines strengthens the dialogue between different stakeholders by bringing in greater clarity in the clinical trial objectives and by providing alignment between the targeted estimand under consideration and the statistical analysis methods.
View Article and Find Full Text PDF